 Braxia Scientific Corp announced that preliminary results from a Phase 2 clinical trial of multi-dose psilocybin-assisted therapy for treatment-resistant depression showed clinically meaningful movements in depression severity. Braxia Scientifics ongoing multi-dose psilocybin trial effectively demonstrated the feasibility of its proprietary psilocybin-assisted therapy protocol with high rates of recruitment and retention with adequate tolerability and safety, the company said. 